PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
43.93
-0.13 (-0.30%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close44.06
Open43.94
Bid43.85 x 1100
Ask44.15 x 1200
Day's Range43.83 - 44.46
52 Week Range33.20 - 44.46
Volume17,163,134
Avg. Volume19,840,206
Market Cap257.522B
Beta0.87
PE Ratio (TTM)11.73
EPS (TTM)3.74
Earnings DateOct 30, 2018
Forward Dividend & Yield1.36 (3.11%)
Ex-Dividend Date2018-08-02
1y Target Est42.39
Trade prices are not sourced from all markets
  • J&J Files for US Approval of Cancer Drug Erdafitinib
    Market Realist18 minutes ago

    J&J Files for US Approval of Cancer Drug Erdafitinib

    On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.

  • Why JNJ Stock Rose ~2.4% Last Week
    Market Realist17 hours ago

    Why JNJ Stock Rose ~2.4% Last Week

    On September 21, Johnson & Johnson (JNJ) stock closed at $142.88, ~0.63% higher than the previous day’s closing price of $141.98. JNJ stock returned ~2.4% last week and is currently trading above its 50-day and 200-day moving averages of $135.35 and $128.52, respectively.

  • AP investigation: Drug prices going up despite Trump promise
    Associated Press18 hours ago

    AP investigation: Drug prices going up despite Trump promise

    President Donald Trump made reducing drug prices a key promise during his election campaign, repeatedly accusing drugmakers of "getting away with murder." At the end of May, he promised that drug companies would be announcing "massive" voluntary drug price cuts within two weeks. Over the first seven months of the year, there were 96 price hikes for every price cut, the AP found. Health and Human Services Secretary Alex Azar, the administration's point person for efforts to lower drug prices, conceded in a recent AP interview that it will be a while before drug prices fall.

  • A Look at Johnson & Johnson’s Valuation This Month
    Market Realist18 hours ago

    A Look at Johnson & Johnson’s Valuation This Month

    On September 23, Johnson & Johnson (JNJ) had a market capitalization of $376.8 billion, and its stock closed ~0.63% higher than the day prior. J&J was trading at a forward PE ratio of 16.8x, while its last-12-month PE ratio was 26.1x. Generally, a high forward PE is a sign of an overvalued or high-growth stock.

  • What Potential Do Analysts See for JNJ Stock?
    Market Realist20 hours ago

    What Potential Do Analysts See for JNJ Stock?

    Healthcare giant Johnson & Johnson (JNJ), which has a market capitalization of $383.3 billion, submitted two new FDA drug applications this month. However, J&J continues to face litigation battles. The company has recently been asked by the Indian government to provide compensation to patients who received its faulty hip implants. In this article, we’ll look at analysts’ recommendations for JNJ stock for the next 12 months.

  • Investopedia23 hours ago

    Resurgent Pfizer Stock Testing 19-Year Resistance

    Dow component Pfizer Inc. ( PFE) has emerged from a multi-year period of weak performance, breaking out above 16-year resistance in the mid-$30s while setting the stage for an assault on 1999's all-time high at $49.99. No specific catalyst is driving the upside, but a deep research pipeline, dozens of partnerships and an impressive roster of profitable drugs have finally encouraged long-term skeptics to enter new positions. Given rising trade tensions, these tailwinds may continue well into the next decade, lifting Pfizer and its blue-chip peers into a series of all-time highs.

  • PR Newswireyesterday

    Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

    Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1) ...

  • ACCESSWIREyesterday

    Today’s Research Reports on Stocks to Watch: Oragenics and Pfizer

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / It was a good day for biotech stocks Pfizer and Oragenics this past Friday. While Oragenics did not have any news, the company is expected to present data ...

  • Why Amarin Corporation Stock Is Exploding Higher Today
    Motley Foolyesterday

    Why Amarin Corporation Stock Is Exploding Higher Today

    Amarin's prescription fish oil pill proves the naysayers wrong in a big way.

  • Investor's Business Daily4 days ago

    IBD Stock Of The Day: Fido's Drugmaker Nears Third Breakout Of 2018

    Zoetis is the IBD Stock Of The Day as shares of Fido's drugmaker loomed near a buy point Friday after rival Elanco Animal Health began its second day of trading.

  • Pfizer (PFE) Gains As Market Dips: What You Should Know
    Zacks4 days ago

    Pfizer (PFE) Gains As Market Dips: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.06, marking a +0.71% move from the previous day.

  • Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
    Zacks4 days ago

    Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status

    Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.

  • Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers
    Zacks4 days ago

    Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers

    The index made strong gains this week as investors shrugged off trade tensions.

  • The Wall Street Journal5 days ago

    [$$] Companies Stockpile Drugs, Chocolate as They Brace for ‘Hard’ Brexit

    LONDON—Some of the world’s biggest companies are drawing up plans for the unplannable: a March divorce between Britain and the European Union, in which even some basic parameters have yet to be hammered out. Big pharmaceutical firms like Pfizer Inc. and GlaxoSmithKline PLC are stockpiling medicine, on orders from the British government, just in case of long delays at the border. Cadbury maker Mondelez International Inc. is boosting supplies of chocolate and other ingredients for the same reason.

  • Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
    Zacks5 days ago

    Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

    Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

  • Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
    Zacks5 days ago

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist5 days ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • Business Wire5 days ago

    Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

    Pfizer Inc. (PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months.

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Pfizer

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist6 days ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • MarketWatch7 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • Business Wire7 days ago

    New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting

    —Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22nd Annual Scientific Meetin

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist7 days ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Watson Health Still the Key Driver for IBM’s AI Business
    Market Realist7 days ago

    Watson Health Still the Key Driver for IBM’s AI Business

    The growing demand for AI in the health industry has encouraged IBM (IBM) to target the health sector with its Watson Health technology. The company’s increasing presence, particularly in oncology and not only in the United States but also in highly populated countries such as China and India, is also contributing to Watson Health’s growth.